Symbols / OVID $2.91 Ovid Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
OVID Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 439.49M
Enterprise Value 327.54M Income -17.14M Sales 7.25M
Book/sh 1.00 Cash/sh 0.53 Dividend Yield —
Payout 0.00% Employees 23 IPO —
P/E — Forward P/E -6.21 PEG —
P/S 60.60 P/B 2.90 P/C —
EV/EBITDA -7.77 EV/Sales 45.16 Quick Ratio 8.40
Current Ratio 8.97 Debt/Eq 10.27 LT Debt/Eq —
EPS (ttm) -0.23 EPS next Y -0.47 EPS Growth —
Revenue Growth 8.45% Earnings 2026-05-12 ROA -21.82%
ROE -17.51% ROIC — Gross Margin 100.00%
Oper. Margin -17.12% Profit Margin -240.13% Shs Outstand 151.03M
Shs Float 101.22M Short Float 6.70% Short Ratio 2.00
Short Interest — 52W High 3.10 52W Low 0.27
Beta -0.03 Avg Volume 3.08M Volume 9.37K
Target Price $5.25 Recom Strong_buy Prev Close $0.00
Price $2.91 Change —
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.25
Mean price target
2. Current target
$2.91
Latest analyst target
3. DCF / Fair value
$-3.06
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.91
Low
$4.00
High
$7.00
Mean
$5.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 reit Wedbush Outperform → Outperform $7
2026-04-09 main HC Wainwright & Co. Buy → Buy $4
2026-03-26 reit BTIG Buy → Buy $4
2026-03-20 main Wedbush Outperform → Outperform $7
2025-12-22 init LifeSci Capital — → Outperform $4
2025-12-22 reit HC Wainwright & Co. Buy → Buy $2
2025-12-11 init Roth Capital — → Buy $3
2025-11-24 main HC Wainwright & Co. Buy → Buy $2
2025-11-17 init Leerink Partners — → Outperform $5
2025-05-27 main HC Wainwright & Co. Buy → Buy $2
2025-03-24 main BTIG Buy → Buy $4
2025-03-24 main HC Wainwright & Co. Buy → Buy $2
2025-03-12 main Wedbush Outperform → Outperform $3
2025-01-29 up Oppenheimer Perform → Outperform $4
2024-12-04 reit HC Wainwright & Co. Buy → Buy $3
2024-09-30 reit HC Wainwright & Co. Buy → Buy $3
2024-08-19 reit HC Wainwright & Co. Buy → Buy $3
2024-07-26 reit HC Wainwright & Co. Buy → Buy $3
2024-07-02 reit HC Wainwright & Co. Buy → Buy $3
2024-06-18 main BTIG Buy → Buy $5
News
RSS: Latest OVID news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-07 PAPADOPOULOS STELIOS B Director — 17,578 $2.56 $45,000
2026-04-07 FRIEDMAN BART Director — 8,789 $2.56 $22,500
2026-04-07 FITZGERALD KEVIN JOSEPH Director — 17,578 $2.56 $45,000
2026-03-23 LEVIN JEREMY M Officer and Director — 47,333 $1.40 $66,266
2026-02-26 RONA JEFFREY A Officer — 68,125 $0.00 $0
2026-02-23 RONA JEFFREY A Officer — 8,541 $1.45 $12,384
2026-02-23 ALEXANDER MARGARET A. Chief Executive Officer — 11,656 $1.45 $16,901
2025-12-15 LEVIN JEREMY M Chief Executive Officer — 71,000 — —
2025-12-08 TAKEDA PHARMACEUTICAL CO., LTD. Beneficial Owner of more than 10% of a Class of Security — 1,250,000 — —
2025-02-26 RONA JEFFREY A Chief Financial Officer — 3,902 $0.56 $2,185
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
7.25
+1181.27%
0.57
+44.39%
0.39
-73.91%
1.50
Operating Revenue
7.25
+1181.27%
0.57
+44.39%
0.39
-73.91%
1.50
Operating Expense
49.69
-20.43%
62.45
+4.66%
59.67
+4.60%
57.05
Research And Development
25.58
-30.42%
36.77
+28.61%
28.59
+16.12%
24.62
Selling General And Administration
24.11
-6.13%
25.68
-17.37%
31.09
-4.15%
32.43
General And Administrative Expense
24.11
-6.13%
25.68
-17.37%
31.09
-4.15%
32.43
Salaries And Wages
10.04
-27.41%
13.84
-19.24%
17.13
+6.60%
16.07
Other Gand A
14.07
+18.71%
11.85
-15.09%
13.95
-14.71%
16.36
Total Expenses
49.69
-20.43%
62.45
+4.66%
59.67
+4.60%
57.05
Operating Income
-42.44
+31.42%
-61.88
-4.39%
-59.28
-6.72%
-55.55
Total Operating Income As Reported
-42.44
+31.42%
-61.88
-4.39%
-59.28
-6.72%
-55.55
EBITDA
-42.17
+31.18%
-61.27
-4.36%
-58.71
-8.39%
-54.17
Normalized EBITDA
-42.17
+34.70%
-64.57
-6.36%
-60.71
-12.09%
-54.17
Reconciled Depreciation
0.27
-55.46%
0.61
+7.92%
0.57
-58.89%
1.38
EBIT
-42.44
+31.42%
-61.88
-4.39%
-59.28
-6.72%
-55.55
Total Unusual Items
—
3.30
+65.00%
2.00
—
Total Unusual Items Excluding Goodwill
—
3.30
+65.00%
2.00
—
Net Income
-17.41
+34.12%
-26.43
+49.50%
-52.34
+3.38%
-54.17
Pretax Income
-17.41
+34.12%
-26.43
+49.50%
-52.34
+3.38%
-54.17
Net Non Operating Interest Income Expense
—
3.90
-20.41%
4.90
—
Net Interest Income
—
3.90
-20.41%
4.90
—
Interest Income Non Operating
—
3.90
-20.41%
4.90
—
Interest Income
—
3.90
-20.41%
4.90
—
Other Income Expense
25.03
-20.55%
31.50
+1475.00%
2.00
+45.02%
1.38
Other Non Operating Income Expenses
25.03
-11.26%
28.20
—
1.38
Gain On Sale Of Security
—
3.30
+65.00%
2.00
—
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-17.41
+34.12%
-26.43
+49.50%
-52.34
+3.38%
-54.17
Net Income From Continuing Operation Net Minority Interest
-17.41
+34.12%
-26.43
+49.50%
-52.34
+3.38%
-54.17
Net Income From Continuing And Discontinued Operation
-17.41
+34.12%
-26.43
+49.50%
-52.34
+3.38%
-54.17
Net Income Continuous Operations
-17.41
+34.12%
-26.43
+49.50%
-52.34
+3.38%
-54.17
Normalized Income
-17.41
+41.43%
-29.73
+45.28%
-54.34
-0.31%
-54.17
Net Income Common Stockholders
-17.41
+34.12%
-26.43
+49.50%
-52.34
+3.38%
-54.17
Otherunder Preferred Stock Dividend
—
—
0.00
0.00
Diluted EPS
-0.23
+37.84%
-0.37
+49.32%
-0.73
+5.19%
-0.77
Basic EPS
-0.23
+37.84%
-0.37
+49.32%
-0.73
+5.19%
-0.77
Basic Average Shares
73.74
+3.99%
70.91
+0.46%
70.58
+0.22%
70.42
Diluted Average Shares
73.74
+3.99%
70.91
+0.46%
70.58
+0.22%
70.42
Diluted NI Availto Com Stockholders
-17.41
+34.12%
-26.43
+49.50%
-52.34
+3.38%
-54.17
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
150.93
+63.76%
92.17
-36.01%
144.03
-7.24%
155.27
Current Assets
74.37
+32.94%
55.94
-48.96%
109.60
-16.58%
131.38
Cash Cash Equivalents And Short Term Investments
69.64
+31.20%
53.08
-49.85%
105.83
-17.96%
129.00
Cash And Cash Equivalents
13.15
-49.99%
26.30
-2.74%
27.04
-39.73%
44.87
Cash Equivalents
12.64
-50.98%
25.78
+5.91%
24.34
-42.07%
42.01
Cash Financial
0.52
-1.15%
0.52
-80.67%
2.70
-5.33%
2.85
Other Short Term Investments
56.48
+110.96%
26.77
-66.02%
78.79
-6.35%
84.13
Receivables
—
—
—
—
Prepaid Assets
—
—
—
—
Other Current Assets
4.73
+65.20%
2.87
-23.88%
3.76
+58.20%
2.38
Total Non Current Assets
76.57
+111.35%
36.23
+5.22%
34.43
+44.14%
23.89
Net PPE
11.86
-10.34%
13.23
-9.77%
14.66
-8.77%
16.07
Gross PPE
13.45
-8.11%
14.64
-6.55%
15.66
-5.94%
16.65
Accumulated Depreciation
-1.59
-12.86%
-1.41
-40.56%
-1.00
-72.18%
-0.58
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
11.61
-9.28%
12.80
-7.90%
13.89
-6.89%
14.92
Machinery Furniture Equipment
1.53
+0.00%
1.53
+4.85%
1.46
+2.81%
1.42
Other Properties
—
—
—
14.92
Leases
0.31
+0.00%
0.31
+0.00%
0.31
-0.10%
0.31
Goodwill And Other Intangible Assets
—
—
0.18
-17.62%
0.22
Investments And Advances
62.77
+199.29%
20.97
+18.99%
17.63
+213.49%
5.62
Long Term Equity Investment
41.96
+100.06%
20.97
+18.99%
17.63
+213.49%
5.62
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
1.93
-4.55%
2.02
-5.51%
2.14
+8.69%
1.97
Total Liabilities Net Minority Interest
20.27
-15.32%
23.94
-57.42%
56.23
+144.55%
22.99
Current Liabilities
8.29
-21.23%
10.52
-8.29%
11.47
+64.10%
6.99
Payables And Accrued Expenses
6.86
-25.38%
9.19
-10.18%
10.23
+58.37%
6.46
Payables
1.96
-38.72%
3.19
-13.80%
3.70
+89.61%
1.95
Accounts Payable
1.96
-38.72%
3.19
-13.80%
3.70
+89.61%
1.95
Current Accrued Expenses
4.90
-18.27%
5.99
-8.12%
6.52
+44.83%
4.50
Current Debt And Capital Lease Obligation
1.43
+7.26%
1.34
+7.22%
1.25
+133.36%
0.53
Current Capital Lease Obligation
1.43
+7.26%
1.34
+7.22%
1.25
+133.36%
0.53
Current Deferred Liabilities
—
—
—
—
Current Deferred Revenue
—
—
—
—
Total Non Current Liabilities Net Minority Interest
11.99
-10.68%
13.42
-70.02%
44.76
+179.69%
16.00
Long Term Debt And Capital Lease Obligation
11.99
-10.68%
13.42
-9.06%
14.76
-7.78%
16.00
Long Term Capital Lease Obligation
11.99
-10.68%
13.42
-9.06%
14.76
-7.78%
16.00
Tradeand Other Payables Non Current
—
—
—
—
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Revenue
—
—
—
—
Other Non Current Liabilities
—
—
30.00
—
Stockholders Equity
130.66
+91.51%
68.23
-22.29%
87.80
-33.62%
132.27
Common Stock Equity
130.66
+91.51%
68.23
-22.29%
87.80
-33.62%
132.27
Capital Stock
0.13
+83.10%
0.07
+0.00%
0.07
+0.75%
0.07
Common Stock
0.13
+83.10%
0.07
+0.00%
0.07
+0.76%
0.07
Preferred Stock
0.00
0.00
0.00
-100.00%
0.00
Share Issued
130.18
+83.33%
71.01
+0.45%
70.69
+0.32%
70.47
Ordinary Shares Number
130.18
+83.33%
71.01
+0.45%
70.69
+0.32%
70.47
Additional Paid In Capital
452.44
+21.47%
372.49
+1.89%
365.59
+2.19%
357.77
Retained Earnings
-321.71
-5.72%
-304.30
-9.51%
-277.87
-23.21%
-225.53
Gains Losses Not Affecting Retained Earnings
-0.20
-477.14%
-0.04
-3600.00%
0.00
+102.37%
-0.04
Other Equity Adjustments
-0.20
-477.14%
-0.04
-3600.00%
0.00
+102.37%
-0.04
Total Equity Gross Minority Interest
130.66
+91.51%
68.23
-22.29%
87.80
-33.62%
132.27
Total Capitalization
130.66
+91.51%
68.23
-22.29%
87.80
-33.62%
132.27
Working Capital
66.08
+45.49%
45.42
-53.71%
98.12
-21.11%
124.39
Invested Capital
130.66
+91.51%
68.23
-22.29%
87.80
-33.62%
132.27
Total Debt
13.42
-9.05%
14.76
-7.79%
16.00
-3.23%
16.54
Capital Lease Obligations
13.42
-9.05%
14.76
-7.79%
16.00
-3.23%
16.54
Net Tangible Assets
130.66
+91.51%
68.23
-22.29%
87.80
-33.51%
132.05
Tangible Book Value
130.66
+91.51%
68.23
-22.29%
87.80
-33.51%
132.05
Available For Sale Securities
20.81
—
—
—
Duefrom Related Parties Current
—
—
—
—
Dueto Related Parties Current
—
—
—
—
Dueto Related Parties Non Current
—
—
—
—
Investmentin Financial Assets
20.81
0.00
—
—
Preferred Stock Equity
—
—
0.00
+0.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-38.33
+31.49%
-55.96
-22.23%
-45.78
+17.10%
-55.23
Cash Flow From Continuing Operating Activities
-38.33
+31.49%
-55.96
-22.23%
-45.78
+17.10%
-55.23
Net Income From Continuing Operations
-17.41
+34.12%
-26.43
+49.50%
-52.34
+3.38%
-54.17
Depreciation Amortization Depletion
0.27
-55.46%
0.61
+7.92%
0.57
-58.89%
1.38
Depreciation
—
—
1.45
+21.84%
1.19
Amortization Cash Flow
—
—
0.15
-23.05%
0.19
Depreciation And Amortization
0.27
-55.46%
0.61
+7.92%
0.57
-58.89%
1.38
Amortization Of Intangibles
—
—
0.15
-23.05%
0.19
Other Non Cash Items
-0.84
+97.44%
-32.91
-1861.44%
-1.68
-37.57%
-1.22
Stock Based Compensation
4.81
-23.41%
6.28
-13.85%
7.29
+11.11%
6.56
Unrealized Gain Loss On Investment Securities
-21.05
-528.61%
-3.35
-67.20%
-2.00
-540.40%
0.45
Change In Working Capital
-4.10
-2636.00%
-0.15
-106.29%
2.39
+128.99%
-8.23
Change In Receivables
—
—
—
0.00
Change In Prepaid Assets
-1.80
-300.44%
0.90
+164.91%
-1.39
-1367.25%
0.11
Change In Payables And Accrued Expense
-2.30
-119.45%
-1.05
-127.82%
3.77
+145.21%
-8.34
Change In Accrued Expense
-1.07
-98.88%
-0.54
-126.57%
2.02
+163.82%
-3.17
Change In Payable
-1.23
-141.02%
-0.51
-129.26%
1.75
+133.82%
-5.17
Change In Account Payable
-1.23
-141.02%
-0.51
-129.26%
1.75
+133.82%
-5.17
Change In Other Working Capital
—
—
—
—
Investing Cash Flow
-49.85
-191.32%
54.59
+2215.23%
-2.58
+97.06%
-87.88
Cash Flow From Continuing Investing Activities
-49.85
-191.32%
54.59
+2216.01%
-2.58
+97.06%
-87.88
Net PPE Purchase And Sale
0.00
+100.00%
-0.07
-77.50%
-0.04
+96.73%
-1.22
Purchase Of PPE
0.00
+100.00%
-0.07
-77.50%
-0.04
+96.73%
-1.22
Capital Expenditure
—
-0.16
-17.52%
-0.14
+90.34%
-1.42
Net Investment Purchase And Sale
-49.85
-191.05%
54.75
+624.55%
7.56
+109.11%
-82.96
Purchase Of Investment
-91.85
-25.40%
-73.25
+34.86%
-112.44
+34.99%
-172.96
Sale Of Investment
42.00
-67.19%
128.00
+6.67%
120.00
+33.33%
90.00
Net Business Purchase And Sale
—
0.00
+100.00%
-10.00
-300.00%
-2.50
Purchase Of Business
—
0.00
+100.00%
-10.00
-300.00%
-2.50
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.09
+7.22%
-0.10
+50.10%
-0.19
Purchase Of Intangibles
—
—
—
-0.19
Net Other Investing Changes
—
0.00
+200.00%
-0.00
+99.90%
-1.00
Financing Cash Flow
75.21
+11991.16%
0.62
-97.96%
30.54
+16802.10%
0.18
Cash Flow From Continuing Financing Activities
75.21
+11991.16%
0.62
-97.96%
30.54
+16802.10%
0.18
Net Common Stock Issuance
75.12
0.00
—
—
Proceeds From Stock Option Exercised
0.09
-85.37%
0.62
+16.26%
0.54
+196.14%
0.18
Net Other Financing Charges
—
—
30.00
—
Changes In Cash
-12.98
-1654.19%
-0.74
+95.85%
-17.83
+87.53%
-142.93
Effect Of Exchange Rate Changes
-0.17
0.00
—
—
Beginning Cash Position
28.23
-2.55%
28.97
-38.09%
46.80
-75.33%
189.73
End Cash Position
15.08
-46.57%
28.23
-2.55%
28.97
-38.09%
46.80
Free Cash Flow
-38.33
+31.69%
-56.12
-22.21%
-45.92
+18.94%
-56.65
Common Stock Issuance
75.12
0.00
—
—
Issuance Of Capital Stock
75.12
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category